Netherlands-based life sciences venture capital firm Forbion has raised more than two billion euros ($2.2 billion) across its two newest funds.
The monies brought in for Forbion Growth Opportunities III and Forbion Ventures VII mean that the total assets under management at Forbion are now 5 billion euros ($5.5 billion).
Both funds exceeded their original target sizes and reached 1.2 billion euros and 890 million euros, respectively.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze